Publication | Open Access

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

MedicineMetronomic TherapyPathologyBronchial NeoplasmAtezolizumab Versus DocetaxelCancer TreatmentOncologyRadiation OncologyLung CancerMolecular Oncology